Literature DB >> 15361245

The immunopathology of experimental visceral leishmaniasis.

Paul M Kaye1, Mattias Svensson, Manabu Ato, Asher Maroof, Rosalind Polley, Simona Stager, Soombul Zubairi, Christian R Engwerda.   

Abstract

Experimental murine infection with the parasites that cause human visceral leishmaniasis (VL) results in the establishment of infection in the liver, spleen, and bone marrow. In most strains of mice, parasites are eventually cleared from the liver, and hepatic resistance to infection results from a coordinated host response involving a broad range of effector and regulatory pathways targeted within defined tissue structures called granulomas. In contrast, parasites persist in the spleen and bone marrow by mechanisms that are less well understood. Parasite persistence is accompanied by the failure of granuloma formation and by a variety of pathologic changes, including splenomegaly, disruption of lymphoid tissue microarchitecture, and enhanced hematopoietic activity. Here, we review the salient features of these distinct tissue responses and highlight the varied roles that cytokines of the tumor necrosis factor family play in immunity to this infection. In addition, we also discuss recent studies aimed at understanding how splenomegaly affects the survival and function of memory cells specific for heterologous antigens, an issue of considerable importance for our understanding of the disease-associated increase in secondary infections characteristic of human VL.

Entities:  

Mesh:

Year:  2004        PMID: 15361245     DOI: 10.1111/j.0105-2896.2004.00188.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  104 in total

1.  Activation of phosphatidylinositol 3-kinase/Akt and impairment of nuclear factor-kappaB: molecular mechanisms behind the arrested maturation/activation state of Leishmania infantum-infected dendritic cells.

Authors:  Bruno Miguel Neves; Ricardo Silvestre; Mariana Resende; Ali Ouaissi; Joana Cunha; Joana Tavares; Inês Loureiro; Nuno Santarém; Ana Marta Silva; Maria Celeste Lopes; Maria Teresa Cruz; Anabela Cordeiro da Silva
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

5.  Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.

Authors:  Alexander B Mullen; Catherine E Lawrence; Emma McFarlane; Xiao-Quing Wei; Katharine C Carter
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

6.  Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection.

Authors:  Asher Maroof; Paul M Kaye
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

7.  Fast high yield of pure Leishmania (Leishmania) infantum axenic amastigotes and their infectivity to mouse macrophages.

Authors:  Juliana Dias Costa; Renata Soares; Léa Cysne Finkelstein; Suzana Côrte-Real; Maria de Nazareth Meirelles; Renato Porrozzi
Journal:  Parasitol Res       Date:  2009-03-18       Impact factor: 2.289

8.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Authors:  Henry W Murray; Yunhua Zhang; Yan Zhang; Vanitha S Raman; Steven G Reed; Xiaojing Ma
Journal:  Infect Immun       Date:  2013-04-15       Impact factor: 3.441

9.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

10.  Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells.

Authors:  Lynette Beattie; Adam Peltan; Asher Maroof; Alun Kirby; Najmeeyah Brown; Mark Coles; Deborah F Smith; Paul M Kaye
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.